145 related articles for article (PubMed ID: 38498388)
1. Assessment of treatment outcomes: cytoreductive surgery compared to radiotherapy in oligometastatic prostate cancer - an in-depth quantitative evaluation and retrospective cohort analysis.
Cheng B; He H; Chen B; Zhou Q; Luo T; Li K; Du T; Huang H
Int J Surg; 2024 Mar; ():. PubMed ID: 38498388
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of cytoreductive surgery for oligometastatic prostate cancer: a meta-analysis.
Cheng B; Ye S; Bai P
World J Surg Oncol; 2021 May; 19(1):160. PubMed ID: 34051809
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive prostatectomy may improve oncological outcomes in patients with oligometastatic prostate cancer: An updated systematic review and meta-analysis.
Chung DY; Kang DH; Jung HD; Lee JY; Kim DK; Ha JS; Jeon J; Cho KS
Investig Clin Urol; 2023 May; 64(3):242-254. PubMed ID: 37341004
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: A retrospective cohort study.
Tsumura H; Ishiyama H; Tabata KI; Sekiguchi A; Kawakami S; Satoh T; Kitano M; Iwamura M
Prostate; 2019 Apr; 79(5):506-514. PubMed ID: 30585345
[TBL] [Abstract][Full Text] [Related]
5. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer.
Ranasinghe W; Chapin BF; Kim IY; Sooriakumaran P; Lawrentschuk N
BJU Int; 2020 Jun; 125(6):792-800. PubMed ID: 32176456
[TBL] [Abstract][Full Text] [Related]
6. Cytoreductive radical prostatectomy or radiation therapy for metastases prostate cancer: Evidence from meta-analysis.
Peng Z; Huang A
Medicine (Baltimore); 2022 Sep; 101(38):e30671. PubMed ID: 36197186
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?
Slaoui A; Albisinni S; Aoun F; Assenmacher G; Al Hajj Obeid W; Diamand R; Regragui S; Touzani A; Bakar A; Mesfioui A; Karmouni T; Ameur A; Elkhader K; Koutani A; Ibnattya A; Roumeguere T; Peltier A
World J Urol; 2019 Nov; 37(11):2343-2353. PubMed ID: 30706122
[TBL] [Abstract][Full Text] [Related]
8. Does surgery benefit patients with oligometastatic or metastatic prostate cancer? - A retrospective cohort study and meta-analysis.
Si S; Zheng B; Wang Z; Niu Z
Prostate; 2021 Aug; 81(11):736-744. PubMed ID: 34056739
[TBL] [Abstract][Full Text] [Related]
9. Oncological Outcome of Combining Cytoreductive Prostatectomy and Metastasis-Directed Radiotherapy in Patients with Prostate Cancer and Bone Oligometastases: A Retrospective Cohort Study.
Xue P; Wu Z; Wang K; Gao G; Zhuang M; Yan M
Cancer Manag Res; 2020; 12():8867-8873. PubMed ID: 33061582
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study.
Rajwa P; Robesti D; Chaloupka M; Zattoni F; Giesen A; Huebner NA; Krzywon A; Miszczyk M; Moll M; Stando R; Cisero E; Semko S; Checcucci E; Devos G; Apfelbeck M; Gatti C; Marra G; van den Bergh RCN; Goldner G; Rasul S; Ceci F; Dal Moro F; Porpiglia F; Gontero P; Bjartell A; Stief C; Heidenreich A; Joniau S; Briganti A; Shariat SF; Gandaglia G;
Eur Urol Oncol; 2023 Oct; ():. PubMed ID: 37845121
[TBL] [Abstract][Full Text] [Related]
11. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.
Franklin J; Eichenauer DA; Becker I; Monsef I; Engert A
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD008814. PubMed ID: 28901021
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive radical prostatectomy versus systemic therapy and radiation therapy in metastatic prostate cancer: A systematic review and meta-analysis.
Shemshaki H; Al-Mamari SA; Geelani IA; Kumar S
Urologia; 2022 Feb; 89(1):16-30. PubMed ID: 34355602
[TBL] [Abstract][Full Text] [Related]
13. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
14. Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer: A Phase II Randomized Controlled Trial.
Dai B; Zhang S; Wan FN; Wang HK; Zhang JY; Wang QF; Kong YY; Ma XJ; Mo M; Zhu Y; Qin XJ; Lin GW; Ye DW
Eur Urol Oncol; 2022 Oct; 5(5):519-525. PubMed ID: 35780048
[TBL] [Abstract][Full Text] [Related]
15. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy for advanced endometrial cancer.
Galaal K; Al Moundhri M; Bryant A; Lopes AD; Lawrie TA
Cochrane Database Syst Rev; 2014 May; 2014(5):CD010681. PubMed ID: 24832785
[TBL] [Abstract][Full Text] [Related]
17. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis.
Hong JC; Ayala-Peacock DN; Lee J; Blackstock AW; Okunieff P; Sung MW; Weichselbaum RR; Kao J; Urbanic JJ; Milano MT; Chmura SJ; Salama JK
PLoS One; 2018; 13(4):e0195149. PubMed ID: 29649281
[TBL] [Abstract][Full Text] [Related]
18. Metastasis-directed therapy and prostate-targeted therapy in oligometastatic prostate cancer: a systematic review.
Miura N; Pradere B; Mori K; Mostafaei H; Quhal F; Misrai V; D'Andrea D; Albisinni S; Papalia R; Saika T; Scarpa RM; Shariat SF; Esperto F
Minerva Urol Nefrol; 2020 Oct; 72(5):531-542. PubMed ID: 32550632
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
20. Current Controversy and Developments Regarding the Cytoreductive Prostatectomy for Oligometastatic Prostate Cancer.
Tian Y; Mao Y; Tang Z; Hu M
Technol Cancer Res Treat; 2023; 22():15330338231216011. PubMed ID: 38105493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
